Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

Moderna’s top executives have sought to reassure investors they will be able to carry out the comeback plans announced in ...

Moderna (MRNA) stock has fallen 71% over the last six months. While there’s still potential for near-term revenue tailwinds ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

Analyst Michael Yee from Jefferies maintained a Hold rating on Moderna (MRNA – Research Report) and decreased the price target to $50.00 from $55.00. Don't Miss our Black Friday Offers: Unlock your ...

CNBC's Jim Cramer reports on the latest news regarding Moderna.

The newest case is the fifth to bring similar allegations against Moderna in the same court, with three others, all filed Nov ...

Moderna reported earnings that exceeded expectations due to effective cost management but still has challenges related to its ...

Moderna said its newest Covid vaccine saw benefits after winning approval in the U.S. three weeks earlier than the last iteration of the shot did in 2023.

In this article, we are going to take a look at where Moderna, Inc. (NASDAQ:MRNA) stands against the other biotech stocks. Biotechnology stocks are among the most volatile in the market due to ...

Moderna's plans include a $1.1 billion reduction in R&D expenses by 2027 to a range of $3.6 billion to $3.8 billion. Rather than spending to explore new products, the company will shift its focus ...

Investing.com -- Shares of Moderna Inc (BMV:MRNA) (NASDAQ:MRNA) were up roughly 7% at $41, while those of Pfizer Inc (NYSE:PFE)were up nearly 2%. Jefferies analysts said Investor sentiment around ...